GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocean Biomedical Inc (NAS:OCEA) » Definitions » Altman Z2-Score

Ocean Biomedical (Ocean Biomedical) Altman Z2-Score : -1,285.71 (As of Jun. 10, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Ocean Biomedical Altman Z2-Score?

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Warning Sign:

Ocean Biomedical has a Altman Z2-Score of -1,285.71, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Ocean Biomedical's Altman Z2-Score or its related term are showing as below:

OCEA' s Altman Z2-Score Range Over the Past 10 Years
Min: -1285.71   Med: -64.44   Max: 29.52
Current: -1285.71

During the past 4 years, Ocean Biomedical's highest Altman Z2-Score was 29.52. The lowest was -1285.71. And the median was -64.44.


Ocean Biomedical Altman Z2-Score Historical Data

The historical data trend for Ocean Biomedical's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocean Biomedical Altman Z2-Score Chart

Ocean Biomedical Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Altman Z2-Score
- -64.44 29.52 16.24

Ocean Biomedical Quarterly Data
Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 16.24 -43.58 -56.00 -1,285.71

Competitive Comparison of Ocean Biomedical's Altman Z2-Score

For the Biotechnology subindustry, Ocean Biomedical's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocean Biomedical's Altman Z2-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocean Biomedical's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Ocean Biomedical's Altman Z2-Score falls into.



Ocean Biomedical Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Ocean Biomedical's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*-28.9234+3.26*-173.8109+6.72*-78.6178+1.05*-0.9865
=-1,285.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Sep. 2023:
Total Assets was $1.03 Mil.
Total Current Assets was $1.03 Mil.
Total Current Liabilities was $30.85 Mil.
Retained Earnings was $-179.20 Mil.
Pre-Tax Income was -14.087 + -11.431 + -72.092 + 15.418 = $-82.19 Mil.
Interest Expense was -0.293 + -0.668 + -0.301 + 0.125 = $-1.14 Mil.
Total Liabilities was $76.26 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(1.031 - 30.851)/1.031
=-28.9234

X2=Retained Earnings/Total Assets
=-179.199/1.031
=-173.8109

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-82.192 - -1.137)/1.031
=-78.6178

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(-75.224 - 0)/76.255
=-0.9865

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Ocean Biomedical has a Altman Z2-Score of -1,285.71 indicating it is in Distress Zones.


Ocean Biomedical  (NAS:OCEA) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Ocean Biomedical Altman Z2-Score Related Terms

Thank you for viewing the detailed overview of Ocean Biomedical's Altman Z2-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocean Biomedical (Ocean Biomedical) Business Description

Traded in Other Exchanges
Address
55 Claverick Street, Room 325, Providence, RI, USA, 02903
Ocean Biomedical Inc is a biopharmaceutical company. It is dedicated towards partnering with inventor-scientists and research institutes to bridge the gap between basic research and clinical development, to get new medicines to the patients who need it most.
Executives
Robert J Sweeney officer: Chief Accounting Officer 20298 CRAIGEN CIRCLE, SARATOGA CA 95070
M Michelle Berrey director 303A COLLEGE ROAD EAST, PRINCETON NJ 08450
William F Owens director C/O KEY ENERGY SERVICES, INC., 1301 MCKINNEY STREET, SUITE 1800, HOUSTON TX 77010
Inderjote S Kathuria officer: Chief Strategy Officer 19W060 AVENUE LATOUR, OAK BROOK IL 60523
Gurinder S Kalra officer: Chief Financial Officer 2305 WASHINGTON STREET, APT 301, SAN FRANCISCO CA 94115
Chirinjeev Kathuria director C/O UPHEALTH HOLDINGS, INC., 14000 S. MILITARY TRAIL #203, DELRAY BEACH FL 33484
Jerome Ringo director 1731 EMBARCADERO ROAD SUITE 200, PALO ALTO CA 94303
Poseidon Bio, Llc 10 percent owner OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Daniel Behr officer: EVP, Innov./Acad. P'ships Head OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Jack A Elias director OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Jonathan Kurtis director OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Elizabeth Ng director, officer: Chief Executive Officer OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Martin D Angle director OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Aesther Healthcare Sponsor, Llc 10 percent owner 515 MADISON AVE., SUITE 8078, NEW YORK NY 10022
Michael L Peterson director 17 CANARY COURT, DANVILLE CA 94526

Ocean Biomedical (Ocean Biomedical) Headlines

From GuruFocus